Most Read Articles
22 Jan 2018
In a symposium chaired by Dr Yoon-Sim Yap of the National Cancer Centre Singapore, renowned regional and international experts in the field of breast cancer, Dr Yen-Shen Lu from Taiwan and Professor Nadia Harbeck from Germany, joined her in providing insights on the current treatment landscape of hormone receptor-positive (HR+) advanced breast cancer. In their respective sessions, they each highlighted new therapeutic options including the optimal use of dual blockade therapy for oestrogenreceptor-positive (ER+) advanced breast cancer for patients in Asia. 
Pearl Toh, 19 Dec 2016
Osimertinib, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), showed significantly greater efficacy than platinum-pemetrexed therapy in advanced non-small cell lung cancer (NSCLC) patients positive for T790M mutation, including those with central nervous system (CNS) metastases, according to data from the AURA3* trial.
Rachel Soon, 06 Feb 2017

An RM6 million shortfall may delay the development of the first immunotherapeutic vaccine to target oral cancers, according to a local team of scientists.

Naomi Adam, 01 Apr 2014

Colorectal cancer (CRC) is one of the most common cancers worldwide and its incidence is rising among Asians. Long-term survival outcomes are poor for CRC because patients often remain undiagnosed until the disease has reached an advanced stage. Panitumumab, a human IgG2 monoclonal antibody with high binding affinity for epidermal growth factor receptors, has shown encouraging results in the treatment of metastatic CRC (mCRC).

Aromatase inhibitors not linked to elevated colorectal cancer risk

12 Jan 2018

Aromatase inhibitors (AIs) do not appear to carry any increase in the risk of developing colorectal cancer, a study reports.

Drawing data from the United Kingdom Clinical Practice Research Datalink, researchers examined breast cancer patients aged ≥55 years who received AIs (n=9,701; median follow-up, 2.4 years) or tamoxifen (n=8,893; median follow-up, 2.9 years) as first-line hormonal therapy.

The risk of incident colorectal cancer in relation to AI vs tamoxifen was estimated by cumulative duration of use and time since initiation using high-dimensional propensity score-adjusted Cox proportional hazards models. All exposures were lagged by 1 year for latency considerations.

Results revealed that the risk of incident colorectal cancer was similar between the AI and tamoxifen groups (incidence rate, 150 per 100,000 person-years in both groups; adjusted hazard ratio [HR], 0.90; 95 percent CI, 0.53–1.52). This was true across analyses stratified by cumulative duration of AI use (p=0.54 for heterogeneity) and time since initiation (p=0.66 for heterogeneity).

The present data show no evidence of an elevated risk of colorectal cancer with AIs when compared with tamoxifen, and this should provide reassurance regarding the safety of AIs to women with breast cancer, researchers said.

“While it is not possible to rule out an increased risk of colorectal cancer with tamoxifen, our findings should be interpreted from context of clinical equipoise as tamoxifen remains the clinically meaningful alternative in management of oestrogen-receptor positive breast cancer,” they explained.

Additional studies with longer follow-up are warranted to confirm the present data, researchers said.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
22 Jan 2018
In a symposium chaired by Dr Yoon-Sim Yap of the National Cancer Centre Singapore, renowned regional and international experts in the field of breast cancer, Dr Yen-Shen Lu from Taiwan and Professor Nadia Harbeck from Germany, joined her in providing insights on the current treatment landscape of hormone receptor-positive (HR+) advanced breast cancer. In their respective sessions, they each highlighted new therapeutic options including the optimal use of dual blockade therapy for oestrogenreceptor-positive (ER+) advanced breast cancer for patients in Asia. 
Pearl Toh, 19 Dec 2016
Osimertinib, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), showed significantly greater efficacy than platinum-pemetrexed therapy in advanced non-small cell lung cancer (NSCLC) patients positive for T790M mutation, including those with central nervous system (CNS) metastases, according to data from the AURA3* trial.
Rachel Soon, 06 Feb 2017

An RM6 million shortfall may delay the development of the first immunotherapeutic vaccine to target oral cancers, according to a local team of scientists.

Naomi Adam, 01 Apr 2014

Colorectal cancer (CRC) is one of the most common cancers worldwide and its incidence is rising among Asians. Long-term survival outcomes are poor for CRC because patients often remain undiagnosed until the disease has reached an advanced stage. Panitumumab, a human IgG2 monoclonal antibody with high binding affinity for epidermal growth factor receptors, has shown encouraging results in the treatment of metastatic CRC (mCRC).